RU2714919C2 - Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков - Google Patents

Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков Download PDF

Info

Publication number
RU2714919C2
RU2714919C2 RU2016109944A RU2016109944A RU2714919C2 RU 2714919 C2 RU2714919 C2 RU 2714919C2 RU 2016109944 A RU2016109944 A RU 2016109944A RU 2016109944 A RU2016109944 A RU 2016109944A RU 2714919 C2 RU2714919 C2 RU 2714919C2
Authority
RU
Russia
Prior art keywords
functional fragment
seq
treatment
patients
neutralizing antibody
Prior art date
Application number
RU2016109944A
Other languages
English (en)
Russian (ru)
Other versions
RU2016109944A3 (enExample
RU2016109944A (ru
Inventor
ВАГНЕР Томас ДР.
Малин КАРЛССОН
КАЛТОФТ Маргит СТАУМ
Original Assignee
Такеда Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Гмбх filed Critical Такеда Гмбх
Publication of RU2016109944A publication Critical patent/RU2016109944A/ru
Publication of RU2016109944A3 publication Critical patent/RU2016109944A3/ru
Application granted granted Critical
Publication of RU2714919C2 publication Critical patent/RU2714919C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RU2016109944A 2013-08-30 2014-09-01 Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков RU2714919C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361871904P 2013-08-30 2013-08-30
US201361871900P 2013-08-30 2013-08-30
US61/871,900 2013-08-30
US61/871,904 2013-08-30
PCT/EP2014/068489 WO2015028657A1 (en) 2013-08-30 2014-09-01 Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics

Publications (3)

Publication Number Publication Date
RU2016109944A RU2016109944A (ru) 2017-10-06
RU2016109944A3 RU2016109944A3 (enExample) 2018-07-09
RU2714919C2 true RU2714919C2 (ru) 2020-02-21

Family

ID=51454704

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016109944A RU2714919C2 (ru) 2013-08-30 2014-09-01 Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков

Country Status (12)

Country Link
US (2) US10745475B2 (enExample)
EP (2) EP3889178A1 (enExample)
JP (4) JP2016536327A (enExample)
KR (3) KR20240090993A (enExample)
CN (2) CN118178647A (enExample)
AU (3) AU2014314053C1 (enExample)
BR (1) BR112016003293A8 (enExample)
CA (1) CA2922251C (enExample)
ES (1) ES2860480T3 (enExample)
MX (2) MX385854B (enExample)
RU (1) RU2714919C2 (enExample)
WO (1) WO2015028657A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3050734A1 (en) 2003-05-15 2004-12-02 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
EP2766029B1 (en) 2011-10-10 2020-03-25 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
AU2015305611B2 (en) 2014-08-18 2020-04-23 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
CN107840885B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
PL3328887T3 (pl) * 2016-09-19 2021-12-27 I-Mab Biopharma (Hangzhou) Co., Ltd. Przeciwciała anty-gm-csf i ich zastosowania
TWI716668B (zh) 2017-02-01 2021-01-21 耶魯大學 心臟衰竭及心腎症候群之精準治療
MX2020006882A (es) 2018-01-05 2020-09-07 Novo Nordisk As Metodos para tratar inflamacion mediada por interleucina-6 sin inmunosupresion.
SG11202008934PA (en) * 2018-03-14 2020-10-29 Univ Indiana Res & Tech Corp Precision medicine for pain: diagnostic biomarkers, pharmacogenomics, and repurposed drugs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111353A2 (en) * 2005-04-18 2006-10-26 Micromet Ag Antibody neutralizers of human granulocyte macrophage colony stimulating factor
WO2008064321A2 (en) * 2006-11-21 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
WO2013053767A1 (en) * 2011-10-10 2013-04-18 Medimmune Limited Treatment for rheumatoid arthritis

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
JPS59147297A (ja) 1983-02-10 1984-08-23 株式会社日立製作所 原子炉圧力容器の耐震構造
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0158487B1 (en) 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
GB8624899D0 (en) 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5070013A (en) 1988-05-31 1991-12-03 Schering Corporation Immunochemical assay for human granulocyte-macrophage colony stimulating factor
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
AU2001232267A1 (en) 2000-02-14 2001-08-20 Japan As Represented By Director General Of Agency Of National Institute Of Infectious Deseases Remedies for hepatitis c
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002324556A1 (en) 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
JP2006500905A (ja) 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
EP1576011B1 (en) 2002-10-30 2009-08-12 Genentech, Inc. Inhibition of il-17 production
EP1755673B1 (en) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9 antibody formulations and uses thereof
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005316405A1 (en) 2004-12-16 2006-06-22 Genentech, Inc. Methods for treating autoimmune disorders
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
NZ564027A (en) 2005-05-18 2011-06-30 Morphosys Ag Anti-GM-CSF antibodies and uses therefor
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
RS55526B1 (sr) 2006-02-08 2017-05-31 Morphotek Inc Antigenski gm-csf peptidi i antitela gm-csf
ES2395839T3 (es) 2006-03-27 2013-02-15 Medimmune Limited Miembro de unión para el receptor GM-CSF
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
MX2010005291A (es) 2007-11-13 2010-11-12 Evec Inc Anticuerpos monoclonales que se unen a hgm-csf y composiciones medicas que comprenden los mismos.
CN102037016B (zh) 2008-04-28 2015-06-03 卡罗拜奥斯制药公司 针对粒细胞巨噬细胞集落刺激因子的抗体
AU2009242088B2 (en) 2008-04-29 2014-08-21 Amgen Research (Munich) Gmbh Inhibitors of GM-CSF and IL-17 for therapy
ES2978209T3 (es) 2008-12-22 2024-09-09 Univ Melbourne Tratamiento del dolor
EP2427495A1 (en) 2009-05-05 2012-03-14 MorphoSys AG Treatment for multiple sclerosis
EP2458990B1 (en) 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
CN102686241A (zh) 2009-12-29 2012-09-19 霍夫曼-拉罗奇有限公司 抗体配制剂
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
EP3916013A1 (en) 2012-09-20 2021-12-01 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
CN109562493B (zh) 2016-08-03 2021-10-26 古河电气工业株式会社 含金属粒子的组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111353A2 (en) * 2005-04-18 2006-10-26 Micromet Ag Antibody neutralizers of human granulocyte macrophage colony stimulating factor
WO2008064321A2 (en) * 2006-11-21 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
WO2013053767A1 (en) * 2011-10-10 2013-04-18 Medimmune Limited Treatment for rheumatoid arthritis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development", ARTHRITIS RESEARCH & THERAPY 2012 (2012), vol. 14, no. 5, pр. 1-9. *
BEHRENS FRANK ET AL, "First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial", ARTHRITIS & RHEUMATISM, & ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY AND ASSOCIATION-OF-RHEUMATOLOGY-HE; WASHINGTON, DC, USA; *
BEHRENS FRANK ET AL, "First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial", ARTHRITIS & RHEUMATISM, & ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY AND ASSOCIATION-OF-RHEUMATOLOGY-HE; WASHINGTON, DC, USA; NOVEMBER 10-14, 2012 (2012), vol. 64, no. 12, pages 4171-4172. *
COOK ANDREW D ET AL, "Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development", ARTHRITIS RESEARCH & THERAPY 2012 (2012), vol. 14, no. 5, pр. 1-9. *
vol. 64, no. 12, pages 4171-4172. *

Also Published As

Publication number Publication date
AU2020203917A1 (en) 2020-07-02
CA2922251C (en) 2023-10-17
BR112016003293A2 (pt) 2017-11-21
RU2016109944A3 (enExample) 2018-07-09
EP3039039A1 (en) 2016-07-06
CN118178647A (zh) 2024-06-14
WO2015028657A1 (en) 2015-03-05
JP2024123249A (ja) 2024-09-10
AU2014314053C1 (en) 2023-11-02
KR20220045064A (ko) 2022-04-12
JP2022105160A (ja) 2022-07-12
US10745475B2 (en) 2020-08-18
CN105705518A (zh) 2016-06-22
MX2021010472A (es) 2021-10-01
US20210171620A1 (en) 2021-06-10
MX385854B (es) 2025-03-18
RU2016109944A (ru) 2017-10-06
KR20240090993A (ko) 2024-06-21
EP3039039B1 (en) 2021-03-10
EP3889178A1 (en) 2021-10-06
KR20160044035A (ko) 2016-04-22
ES2860480T3 (es) 2021-10-05
CA2922251A1 (en) 2015-03-05
AU2014314053B2 (en) 2020-03-12
MX2016002177A (es) 2016-06-28
US11795216B2 (en) 2023-10-24
US20160355584A1 (en) 2016-12-08
JP2020109108A (ja) 2020-07-16
BR112016003293A8 (pt) 2022-08-16
AU2014314053A1 (en) 2016-02-11
AU2023210647A1 (en) 2023-10-12
JP2016536327A (ja) 2016-11-24

Similar Documents

Publication Publication Date Title
US11795216B2 (en) Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
ES2733712T3 (es) Métodos para tratar la espondilitis anquilosante utilizando anticuerpos anti-IL-17
JP5905534B2 (ja) 多発性硬化症を治療する方法
KR101681331B1 (ko) 치료를 위한 ｇｍ-ｃｓｆ 및 ｉｌ-17의 억제제
EP3191120B1 (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
US20150291689A1 (en) Compositions and Methods for Treating Rheumatoid Arthritis
EP3868785A1 (en) Anti-cd28 humanized antibodies formulated for administration to humans
CN112512578A (zh) 结合cd123和cd3的双特异性抗体的给药
JP2005529152A (ja) 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療
HK40062612A (en) Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20211230